Acadia Pharmaceuticals | ACAD - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cara Therapeutics USD 14.5M 6.44M 2026-03
Corcept Therapeutics USD 705.78M 67.79M 2026-06
Cytokinetics USD -826.57M 166.94M 2026-03
Eisai JPY 906.56B 7.57B 2026-06
Eli Lilly USD 31.2B 4.66B 2026-03
Incyte USD 6.34B 721.58M 2026-06
J&J USD 84.97B 3.78B 2026-06
Moderna USD 6.76B 647M 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 312.62M 32.14M 2026-03
PTC Therapeutics USD -165.36M 15.1M 2026-06
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Vertex Pharmaceuticals USD 20.25B 886M 2026-06